NSRX
Nasus Pharma Ltd
$2.90
-0.34%
$34.1M
No data for this timeframe.
Vol
Market Cap$34.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Insider Activity2B / 0S
Insider Net $$41.5K
Reddit Sentiment67° Warm
SEC Reports5
Press Releases2
Recent Activity
May 1, 2026
other
Nasus Pharma to Participate in Upcoming Investor Conferences
<p align="start">TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX)
Apr 22, 2026
Insider
Teleman Dan Benjamin bought 2,900 shares
Chief Executive Officer @ $3.76 ($10.9K)
Apr 1, 2026
SEC
Nasus Pharma's IPO registration has become effective, allowing the company to begin selling shares to the public. This f
EFFECT — Impact 6/10
Mar 31, 2026
Insider
Teleman Dan Benjamin bought 15,000 shares
Chief Executive Officer @ $2.04 ($30.6K)
Mar 28, 2026
SEC
Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, filed a Form 3 disclosing ownership of unvested stock options for 126,197 o
3 — Impact 2/10
Mar 28, 2026
SEC
Nasus Pharma Ltd insiders filed Form 3s disclosing ownership of securities, including options and warrants. Founder & Ex
3 — Impact 3/10
Mar 25, 2026
Press
Nasus Pharma released its 2025 annual results and provided a business update, highlighting positive Phase 2 data for its
Impact 6/10
Mar 16, 2026
Press
Nasus Pharma announced positive Phase 2 results for its intranasal epinephrine candidate NS002, showing significantly fa
Impact 8/10
Price Targets
$19.67
+578.2% upside
Strong Buy
Current $2.90
Low $18.00
Median $19.00
High $22.00
3 analysts
$18.00
$22.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 26, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Dec 18, 2025 | Citizens | INITIATE | Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 ▼ -21.1% | $-0.27 — $-0.19 | 2 | |
| Next Q | $-0.23 ▲ +17.9% | $-0.28 — $-0.18 | 2 | |
| Current FY | $-0.97 ▲ +4.4% | $-1.02 — $-0.93 | -35% YoY | 2 |
| Next FY | $-1.32 ▲ +26.3% | $-1.79 — $-0.85 | -35% YoY | 2 |
Latest Reports
BEARISH
EFFECT
6/10
Nasus Pharma's IPO registration has become effective, allowing the company to begin selling shares to the public. This f
Apr 1, 2026
NEUTRAL
3
2/10
Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, filed a Form 3 disclosing ownership of unvested stock options for 126,197 o
Mar 28, 2026
MIXED
Press
6/10
Nasus Pharma released its 2025 annual results and provided a business update, highlighting positive Phase 2 data for its
Mar 25, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 22, 2026 | Teleman Dan | BUY | $10.9K |
| Mar 31, 2026 | Teleman Dan | BUY | $30.6K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
1 unique insiders with 2 transactions. Net insider value: $41.5K ($41.5K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Teleman Dan Benjamin | Chief Executive Officer | BUY | 2,900 | $3.76 | $10.9K |
| Mar 31, 2026 | Teleman Dan Benjamin | Chief Executive Officer | BUY | 15,000 | $2.04 | $30.6K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
BEARISH
EFFECT
6/10
Nasus Pharma's IPO registration has become effective, allowing the company to begin selling shares t
Apr 1, 2026
NEUTRAL
3
2/10
Rubin Eyal, CFO and EVP of Nasus Pharma Ltd, filed a Form 3 disclosing ownership of unvested stock o
Mar 28, 2026
NEUTRAL
3
3/10
Nasus Pharma Ltd insiders filed Form 3s disclosing ownership of securities, including options and wa
Mar 28, 2026
NEUTRAL
EFFECT
5/10
Nasus Pharma Ltd's Form F-1 registration statement has become effective, allowing the company to pro
Mar 16, 2026
BEARISH
F-1
6/10
Nasus Pharma is a clinical-stage Israeli pharmaceutical company developing intranasal powder-based d
Mar 2, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.67 mean target
+578.2% upside
Strong Buy (3.00)
$18.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $2.90 |
| Target Low | $18.00 |
| Target Mean | $19.67 |
| Target Median | $19.00 |
| Target High | $22.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.23 | $-0.27 | $-0.19 | — | -21.1% | — | $0.0B | — | 2 |
| Next Q 2026-06-30 |
$-0.23 | $-0.28 | $-0.18 | — | +17.9% | — | $0.0B | — | 2 |
| Current FY 2026-12-31 |
$-0.97 | $-1.02 | $-0.93 | -35.4% | +4.4% | — | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.32 | $-1.79 | $-0.85 | -35.4% | +26.3% | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $-0.190 | -0.040 |
| 30d ago | $-0.190 | -0.040 |
| 60d ago | $0.000 | -0.230 |
| 90d ago | $0.000 | -0.230 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Dec 18, 2025 | Citizens | INITIATE | — | Market Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 28, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 1, 2026
other
Nasus Pharma to Participate in Upcoming Investor Conferences
<p align="start">TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-sta
Mar 25, 2026
earnings
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
<p align="center"><i>Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significa
Mar 18, 2026
short_interest
FTD: NSRX — 276,233 shares ($0.8M) failed to deliver
Settlement: 20260318, Price: $2.79, FTD Value: $770,690.07, NASUS PHARMA LTD ORD SHS(ISR)
Mar 17, 2026
short_interest
FTD: NSRX — 350,156 shares ($1.1M) failed to deliver
Settlement: 20260317, Price: $3.10, FTD Value: $1,085,483.6, NASUS PHARMA LTD ORD SHS(ISR)
Mar 16, 2026
fda
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
<p align="center"><i>NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T
Mar 9, 2026
other
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
<p>TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical co
Feb 20, 2026
other
Nasus Pharma to Participate in Upcoming Investor Conferences
<p>TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical com